Chun Chieh Lin1, Suanna S Bruinooge2, M Kelsey Kirkwood2, Christine Olsen2, Ahmedin Jemal2, Dean Bajorin2, Sharon H Giordano2, Michael Goldstein2, B Ashleigh Guadagnolo2, Michael Kosty2, Shane Hopkins2, James B Yu2, Anna Arnone2, Amy Hanley2, Stephanie Stevens2, Dawn L Hershman2. 1. Chun Chieh Lin and Ahmedin Jemal, American Cancer Society, Atlanta, GA; Suanna S. Bruinooge, M. Kelsey Kirkwood, and Amy Hanley, American Society of Clinical Oncology, Alexandria; Anna Arnone and Stephanie Stevens, American Society for Radiation Oncology, Fairfax, VA; Christine Olsen, Massachusetts General Hospital; Michael Goldstein, Beth Israel Deaconess Medical Center, Boston, MA; Dean Bajorin, Memorial Sloan Kettering Cancer Center; Dawn L. Hershman, Columbia University Medical Center, New York, NY; Sharon H. Giordano and B. Ashleigh Guadagnolo, The University of Texas MD Anderson Cancer Center, Houston, TX; Michael Kosty, Scripps Clinic, La Jolla, CA; Shane Hopkins, William R. Bliss Cancer Center, Ames, IA; and James B. Yu, Yale University School of Medicine, New Haven, CT. anna.lin@cancer.org. 2. Chun Chieh Lin and Ahmedin Jemal, American Cancer Society, Atlanta, GA; Suanna S. Bruinooge, M. Kelsey Kirkwood, and Amy Hanley, American Society of Clinical Oncology, Alexandria; Anna Arnone and Stephanie Stevens, American Society for Radiation Oncology, Fairfax, VA; Christine Olsen, Massachusetts General Hospital; Michael Goldstein, Beth Israel Deaconess Medical Center, Boston, MA; Dean Bajorin, Memorial Sloan Kettering Cancer Center; Dawn L. Hershman, Columbia University Medical Center, New York, NY; Sharon H. Giordano and B. Ashleigh Guadagnolo, The University of Texas MD Anderson Cancer Center, Houston, TX; Michael Kosty, Scripps Clinic, La Jolla, CA; Shane Hopkins, William R. Bliss Cancer Center, Ames, IA; and James B. Yu, Yale University School of Medicine, New Haven, CT.
Abstract
PURPOSE: Geographic access to care may be associated with receipt of chemotherapy but has not been fully examined. This study sought to evaluate the association between density of oncologists and travel distance and receipt of adjuvant chemotherapy for colon cancer within 90 days of colectomy. PATIENTS AND METHODS: Patients in the National Cancer Data Base with stage III colon cancer, diagnosed between 2007 and 2010, and age 18 to 80 years were selected. Generalized estimating equation clustering by hospital service area was conducted to examine the association between geographic access and receipt of oncology services, controlling for patient sociodemographic and clinical characteristics. RESULTS: Of 34,694 patients in the study cohort, 75.7% received adjuvant chemotherapy within 90 days of colectomy. Compared with travel distance less than 12.5 miles, patients who traveled 50 to 249 miles (odds ratio [OR], 0.87; P=.009) or ≥250 miles (OR, 0.36; P<.001) had decreased likelihood of receiving adjuvant chemotherapy. Density level of oncologists was not statistically associated with receipt of adjuvant chemotherapy (low v high density: OR, 0.98; P=.77). When stratifying analyses by insurance status, non-privately insured patients who resided in areas with low density of oncologists were less likely to receive adjuvant chemotherapy (OR, 0.85; P=.03). CONCLUSION: Increased travel burden was associated with a decreased likelihood of receiving adjuvant chemotherapy, regardless of insurance status. Patients with nonprivate insurance who resided in low-density oncologist areas were less likely to receive adjuvant chemotherapy. If these findings are validated prospectively, interventions to decrease geographic barriers may improve the timeliness and quality of colon cancer treatment.
PURPOSE: Geographic access to care may be associated with receipt of chemotherapy but has not been fully examined. This study sought to evaluate the association between density of oncologists and travel distance and receipt of adjuvant chemotherapy for colon cancer within 90 days of colectomy. PATIENTS AND METHODS: Patients in the National Cancer Data Base with stage III colon cancer, diagnosed between 2007 and 2010, and age 18 to 80 years were selected. Generalized estimating equation clustering by hospital service area was conducted to examine the association between geographic access and receipt of oncology services, controlling for patient sociodemographic and clinical characteristics. RESULTS: Of 34,694 patients in the study cohort, 75.7% received adjuvant chemotherapy within 90 days of colectomy. Compared with travel distance less than 12.5 miles, patients who traveled 50 to 249 miles (odds ratio [OR], 0.87; P=.009) or ≥250 miles (OR, 0.36; P<.001) had decreased likelihood of receiving adjuvant chemotherapy. Density level of oncologists was not statistically associated with receipt of adjuvant chemotherapy (low v high density: OR, 0.98; P=.77). When stratifying analyses by insurance status, non-privately insured patients who resided in areas with low density of oncologists were less likely to receive adjuvant chemotherapy (OR, 0.85; P=.03). CONCLUSION: Increased travel burden was associated with a decreased likelihood of receiving adjuvant chemotherapy, regardless of insurance status. Patients with nonprivate insurance who resided in low-density oncologist areas were less likely to receive adjuvant chemotherapy. If these findings are validated prospectively, interventions to decrease geographic barriers may improve the timeliness and quality of colon cancer treatment.
Authors: R G Roetzheim; N Pal; D J van Durme; D Wathington; J M Ferrante; E C Gonzalez; J P Krischer Journal: J Am Acad Dermatol Date: 2000-08 Impact factor: 11.527
Authors: Carrie N Klabunde; Julie M Legler; Joan L Warren; Laura-Mae Baldwin; Deborah Schrag Journal: Ann Epidemiol Date: 2007-05-25 Impact factor: 3.797
Authors: Laura-Mae Baldwin; Yong Cai; Eric H Larson; Sharon A Dobie; George E Wright; David C Goodman; Barbara Matthews; L Gary Hart Journal: J Rural Health Date: 2008 Impact factor: 4.333
Authors: Justin A Yu; Kristin N Ray; Seo Young Park; Amanda Barry; Cardinale B Smith; Peter G Ellis; Yael Schenker Journal: J Oncol Pract Date: 2018-11-08 Impact factor: 3.840
Authors: J M Vahl; A von Witzleben; C Welke; J Doescher; M N Theodoraki; M Brand; P J Schuler; J Greve; T K Hoffmann; S Laban Journal: Eur Arch Otorhinolaryngol Date: 2021-04-20 Impact factor: 2.503
Authors: Michelle S Wong; David T Grande; Nandita Mitra; Archana Radhakrishnan; Charles C Branas; Katelyn R Ward; Craig E Pollack Journal: Med Care Date: 2017-09 Impact factor: 2.983
Authors: April D Kimmel; Steven P Masiano; Rose S Bono; Erika G Martin; Faye Z Belgrave; Adaora A Adimora; Bassam Dahman; Hadiza Galadima; Lindsay M Sabik Journal: AIDS Care Date: 2018-05-30
Authors: Gabrielle B Rocque; Courtney P Williams; Harold D Miller; Andres Azuero; Stephanie B Wheeler; Maria Pisu; Olivia Hull; Rodney P Rocconi; Kelly M Kenzik Journal: J Clin Oncol Date: 2019-06-11 Impact factor: 44.544
Authors: Craig Evan Pollack; Katrina A Armstrong; Nandita Mitra; Xinwei Chen; Katelyn R Ward; Archana Radhakrishnan; Michelle S Wong; Justin E Bekelman; Charles C Branas; Karin V Rhodes; David T Grande Journal: Cancer Date: 2017-07-20 Impact factor: 6.860